4D Molecular Therapeutics (FDMT) Net Income (2020 - 2026)

4D Molecular Therapeutics (FDMT) has reported Net Income for 7 consecutive years, with -$94.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income fell 91.98% year-over-year to -$94.9 million; the TTM figure through Mar 2026 stood at -$252.7 million (down 13.1% YoY), while the FY2025 annual figure was -$298.6 million, down 3.38% from the prior year.
• Net Income slipped to -$94.9 million in Q1 2026 per FDMT's latest filing, from $18.0 million in the prior quarter.
• Across five years, Net Income topped out at $18.0 million in Q4 2025 and bottomed at -$94.9 million in Q1 2026.
• Historically, Net Income has averaged -$48.4 million across 5 years, with a median of -$47.3 million in 2022.
• Annual changes were most pronounced in 2022 — Net Income plunged 217.09% — and 2025, when it jumped 135.65%.
• 4D Molecular Therapeutics' Net Income stood at -$30.3 million in 2022, then dropped by 9.21% to -$33.1 million in 2023, then tumbled by 52.85% to -$50.6 million in 2024, then surged by 135.65% to $18.0 million in 2025, then plunged by 626.73% to -$94.9 million in 2026.
• Business Quant data shows FDMT's Net Income at -$94.9 million in Q1 2026, $18.0 million in Q4 2025, and -$85.9 million in Q3 2025.